Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Heron Therapeutics (HRTX)

Heron Therapeutics (HRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Heron Therapeutics Announces Publication of Results from EPOCH 2 Follow-On Study, a Phase 2b Study of HTX-011 in Patients Undergoing Hernia Repair Surgery

, /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of...

HRTX : 14.61 (+0.27%)
Heron Therapeutics to Present at Cantor Virtual Global Healthcare Conference

, /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of...

HRTX : 14.61 (+0.27%)
Biotech Stock Roundup: GILD Submits BLA, ALBO Gains on Study Data & More

The biotech sector remains in focus with regulatory and other pipeline updates.

GILD : 62.25 (unch)
AMRN : 3.81 (+4.67%)
AKBA : 2.48 (+0.81%)
HRTX : 14.61 (+0.27%)
ALBO : 33.31 (+2.37%)
Heron Therapeutics Announces Successful Outcome of FDA Type A Meeting to Discuss HTX-011 for the Management of Postoperative Pain

, /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of...

HRTX : 14.61 (+0.27%)
Interesting HRTX Put And Call Options For October 16th

Investors in Heron Therapeutics Inc saw new options begin trading this week, for the October 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the HRTX options...

HRTX : 14.61 (+0.27%)
Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -3.39% and 38.64%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

HRTX : 14.61 (+0.27%)
Heron Therapeutics: 2Q Earnings Snapshot

SAN DIEGO (AP) _ Heron Therapeutics Inc. (HRTX) on Wednesday reported a loss of $55.2 million in its second quarter.

HRTX : 14.61 (+0.27%)
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate Updates

, /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best–in-class treatments to address some...

HRTX : 14.61 (+0.27%)
Heron Therapeuti Rises 1.99% on Heavy Volume: Watch For Potential Pullback

Heron Therapeuti (NASDAQ:HRTX) traded in a range yesterday that spanned from a low of $19.76 to a high of $20.10. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high...

HRTX : 14.61 (+0.27%)
Heron Therapeuti Up 43.4% Since SmarTrend Uptrend Call (HRTX)

SmarTrend identified an Uptrend for Heron Therapeuti (NASDAQ:HRTX) on April 8th, 2020 at $13.73. In approximately 2 months, Heron Therapeuti has returned 43.45% as of today's recent price of $19.70.

HRTX : 14.61 (+0.27%)
Heron Therapeutics Announces Publication of Results from Study 209, a Phase 2b Study of HTX-011 in Patients Undergoing Total Knee Arthroplasty

, /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of...

HRTX : 14.61 (+0.27%)
Heron Therapeutics Announces Initiation of Phase 1b/2 Clinical Study of HTX-034 for the Treatment of Postoperative Pain

, /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some...

HRTX : 14.61 (+0.27%)
Interesting HRTX Put And Call Options For July 17th

Investors in Heron Therapeutics Inc saw new options become available today, for the July 17th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time...

HRTX : 14.61 (+0.27%)
Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 9.52% and 25.36%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

HRTX : 14.61 (+0.27%)
Heron Therapeutics: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Heron Therapeutics Inc. (HRTX) on Wednesday reported a loss of $51.6 million in its first quarter.

HRTX : 14.61 (+0.27%)
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2020 and Highlights Recent Corporate Updates

, /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of...

HRTX : 14.61 (+0.27%)
Heron Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important...

HRTX : 14.61 (+0.27%)
Downtrend Call Working As Heron Therapeuti Stock Falls 47.9% (HRTX)

SmarTrend identified a Downtrend for Heron Therapeuti (NASDAQ:HRTX) on February 18th, 2020 at $20.76. In approximately 1 month, Heron Therapeuti has returned 47.88% as of today's recent price of $10.82....

HRTX : 14.61 (+0.27%)
Heron Therapeuti Shares Down 45.9% Since SmarTrend's Sell Call (HRTX)

SmarTrend identified a Downtrend for Heron Therapeuti (NASDAQ:HRTX) on February 18th, 2020 at $20.76. In approximately 1 month, Heron Therapeuti has returned 45.91% as of today's recent price of $11.23....

HRTX : 14.61 (+0.27%)
Shares of Alkermes Plc Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (ALKS , HRTX , IRWD , ICPT , BLUE )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

ALKS : 16.74 (+1.27%)
HRTX : 14.61 (+0.27%)
IRWD : 9.45 (-0.11%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar